Cargando…

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study

OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Montag, Laura J, Horneff, Gerd, Hoff, Paula, Klein, Ariane, Kallinich, Tilmann, Foeldvari, Ivan, Seipelt, Eva, Tatsis, Stefanie, Peer Aries, MD, Niewerth, Martina, Klotsche, Jens, Minden, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608545/
https://www.ncbi.nlm.nih.gov/pubmed/36283758
http://dx.doi.org/10.1136/rmdopen-2022-002520
_version_ 1784818799339372544
author Montag, Laura J
Horneff, Gerd
Hoff, Paula
Klein, Ariane
Kallinich, Tilmann
Foeldvari, Ivan
Seipelt, Eva
Tatsis, Stefanie
Peer Aries, MD
Niewerth, Martina
Klotsche, Jens
Minden, Kirsten
author_facet Montag, Laura J
Horneff, Gerd
Hoff, Paula
Klein, Ariane
Kallinich, Tilmann
Foeldvari, Ivan
Seipelt, Eva
Tatsis, Stefanie
Peer Aries, MD
Niewerth, Martina
Klotsche, Jens
Minden, Kirsten
author_sort Montag, Laura J
collection PubMed
description OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medications taken (disease-modifying antirheumatic drugs (DMARDs)/prescription/over-the-counter drugs, but excluding most local therapies) classified according to the Anatomical Therapeutic Chemical Classification System were included in this analysis. Medication use at last follow-up was evaluated by sex, JIA category and time from symptom onset to the first biological DMARD (bDMARD) start. RESULTS: A total of 1306 young adults (68% female) with JIA and a mean disease duration of 13.6±6 years were included in the study. Patients reported using on average 2.4±2.1 medicines and 1.5±1.7 non-DMARD medicines, respectively, at the last follow-up. Almost a quarter of the patients reported polypharmacy. The higher the number of medications used was, the higher the disease activity, pain and fatigue, and the lower the quality of life of patients. Medication usage differed significantly between sexes and JIA categories, being highest in patients with rheumatoid factor-positive polyarthritis and systemic JIA. The number of medications used was significantly associated with the time from symptom onset to bDMARD start. Patients taking opioids or antidepressants had a particularly high disease burden and had received bDMARDs an average of 2 years later than patients not taking these medications. CONCLUSION: Medication use in adults with JIA varies depending on sex, JIA category, and the time between symptom onset and initiation of treatment with bDMARD.
format Online
Article
Text
id pubmed-9608545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96085452022-10-28 Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study Montag, Laura J Horneff, Gerd Hoff, Paula Klein, Ariane Kallinich, Tilmann Foeldvari, Ivan Seipelt, Eva Tatsis, Stefanie Peer Aries, MD Niewerth, Martina Klotsche, Jens Minden, Kirsten RMD Open Paediatric Rheumatology OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medications taken (disease-modifying antirheumatic drugs (DMARDs)/prescription/over-the-counter drugs, but excluding most local therapies) classified according to the Anatomical Therapeutic Chemical Classification System were included in this analysis. Medication use at last follow-up was evaluated by sex, JIA category and time from symptom onset to the first biological DMARD (bDMARD) start. RESULTS: A total of 1306 young adults (68% female) with JIA and a mean disease duration of 13.6±6 years were included in the study. Patients reported using on average 2.4±2.1 medicines and 1.5±1.7 non-DMARD medicines, respectively, at the last follow-up. Almost a quarter of the patients reported polypharmacy. The higher the number of medications used was, the higher the disease activity, pain and fatigue, and the lower the quality of life of patients. Medication usage differed significantly between sexes and JIA categories, being highest in patients with rheumatoid factor-positive polyarthritis and systemic JIA. The number of medications used was significantly associated with the time from symptom onset to bDMARD start. Patients taking opioids or antidepressants had a particularly high disease burden and had received bDMARDs an average of 2 years later than patients not taking these medications. CONCLUSION: Medication use in adults with JIA varies depending on sex, JIA category, and the time between symptom onset and initiation of treatment with bDMARD. BMJ Publishing Group 2022-10-25 /pmc/articles/PMC9608545/ /pubmed/36283758 http://dx.doi.org/10.1136/rmdopen-2022-002520 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Paediatric Rheumatology
Montag, Laura J
Horneff, Gerd
Hoff, Paula
Klein, Ariane
Kallinich, Tilmann
Foeldvari, Ivan
Seipelt, Eva
Tatsis, Stefanie
Peer Aries, MD
Niewerth, Martina
Klotsche, Jens
Minden, Kirsten
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title_full Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title_fullStr Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title_full_unstemmed Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title_short Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
title_sort medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
topic Paediatric Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608545/
https://www.ncbi.nlm.nih.gov/pubmed/36283758
http://dx.doi.org/10.1136/rmdopen-2022-002520
work_keys_str_mv AT montaglauraj medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT horneffgerd medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT hoffpaula medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT kleinariane medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT kallinichtilmann medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT foeldvariivan medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT seipelteva medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT tatsisstefanie medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT peerariesmd medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT niewerthmartina medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT klotschejens medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy
AT mindenkirsten medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy